Table 2.

Scheduled measurements of primary and secondary outcomes

Measurement	Baseline	Injection	2 weeks fu	4 weeks fu	8 weeks fu	12 weeks fu	24 weeks fu
Primary outcome measure
KOOS pain subscale	x		x	x	x	x	x
Secondary outcome measures
Adverse events			x
Hospitalization			x	x	x	x	x
Co-interventions (iMCQ)			x	x	x	x	x
Medication use for knee OA	x		x	x	x	x	x
Re-injection with glucocorticoid					x	x	x
KOOS stiffness	x		x	x	x	x	x
KOOS function in daily living	x		x	x	x	x	x
KOOS sports and recreation	x		x	x	x	x	x
KOOS QoL	x		x	x	x	x	x
ICOAP	x		x	x	x	x	x
OMERACT OARSI responder criteria			x	x	x	x	x
Knee pain over past week (NRS)	x	x	x	x	x	x	x
Perceived recovery (Likert scale)			x	x	x	x	x
Knee complaint characteristics	x		x	x	x	x	x
Health related QoL	x
Additional measurements
Radiograph of study knee						x
Check of ACR criteria		x
Painfulness of injection (NRS)			x
Demographic information	x
Co-morbidity	x
Physical activity over the past week (IPAQ short)	x
Neuropathic pain (Modified painDETECT Questionnaire)	x
Patients’ preferred injection site	x
Patients’ expected treatment response	x